Now that insulin prices are being controlled in the U.S., both companies are focused on the new source of revenue from the GLP-1 market
of the CY 2026 OPPS/ASC proposed rule, we also proposed that if more recent data are subsequently available (for example, a more recent estimate of the PPI for Pharmaceuticals for Human Use, Prescription), we would use such data, if appropriate, to determine the CY 2026 diagnostic radiopharmaceutical packaging threshold in the final rule
One common error: assuming detectability equals bioactivity
Insurance providers that may cover semaglutide include United Healthcare, which frequently does so with prior authorization for a BMI of 30 or higher, or 27 with weight-related conditions
Though controversial in longevity medicine, its systemic regenerative effects are well-documented in deficient populations
The takeaway: meaningful progress often happens gradually, and the habits that produce lasting results arent always the ones that generate the fastest changes on the scale
